TeamDrive
RUS
Leonid Melamed

Leonid Melamed

Founding Partner, Chairman of The Board of Directors

Телефоны:

+7 495 545-39-12

Send message

​Leonid has almost 30 years of management experience at large companies in various market sectors.

Leonid – one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the American firm Domain Associates LLC. RusnanoMedInvest LLC (RMI) was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. Russian pharmaceutical company NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Leonid Melamed is the co-founder and Chairman of the Board of Directors of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is NovaMedica LLC. At the present time Leonid is a member of the Board of Directors of RusnanoMedInvest and from 2012 to 2017 he was a member of the Board of NovaMedica.

Leonid also is the co-founder and member of the Board of Directors of Doctor Ryadom (network of medical clinics), which among the first in Russia began to provide telemedicine services to its patients.

Earlier Leonid was the President and Chairman of the Management Board and member of the Board of Directors of Sistema JFSC (from 2008 to 2011). From 2006 to 2008, Leonid ran the telecommunications company Mobile TeleSystems (MTS OJSC) as President and Chairman of the Management Board. For 15 years from 1991 to 2006 Leonid participated in the creation and development of ROSNO insurance company. In 2003 he was the head of ROSNO as CEO and Chairman of the Management Board.

His personal “portfolio” includes Russneft OJSC as Chairman of the Board of Directors (2010-2012) and VTB OJSC as a member of the Supervisory Board (2012-2013).

Currently, Leonid is a member of the Government Expert Council of the Russian Federation, which was established to involve the business community in the preparation and implementation of the Government’s decisions.

Leonid graduated with honours from I.M. Sechenov Moscow Medical Academy and in 2006 became a Doctor of Medical Sciences.

Media Center

  • 14 August 2018

    FPI conducts preclinical trials of drug intended to save seriously injured

    Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).

  • 13 August 2018

    Russian scientists developed a novel method of collecting blood samples

    Russian researchers have developed a non-contact method of taking blood samples. Laser device will provide absolute sterility, minimal pain for a patient, rapid wound healing and high cost-effectiveness compared to automatic lancets with a retractable needle.

  • 10 August 2018

    Tomsk researchers developed new nanosilver catalysts

    The Tomsk Polytechnic University (TPU) research team proposed to use catalysts based on silver nanoparticles in liquid-phase oxidation of alcohols. This will allow making the process of alcohol oxidation more ecological and cost-effective, comparing with more traditional high-temperature gas-phase oxidation or with toxic reagents.

  • 09 August 2018

    Priority in drug procurement is considered the most effective to reduce imports

    In 2018, the number of pharmaceutical companies believing that the most effective way to reduce the share of imported drugs is further restriction or ban on participation of foreign producers in public procurement, increased to 63%.

Read more